Sophia Abene is the Assistant Editor for Contagion. You can email her at abenes@mjhlifesciences.com.
From Poultry to Public Health: Understanding the H5N1 Threat
October 29th 2024Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.
Read More
Exploring The Challenges and Insights in Long COVID Treatment and Management
Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.
Read More
E coli Outbreak Linked to McDonald’s Quarter Pounders, Onion Supplier Issues Recall
Published: October 25th 2024 | Updated: October 25th 2024Links to consumed hamburgers have resulted in 75 infections and one fatality, prompting an investigation of the slivered onions used on these beef patties.
Read More
Day 1 Recap from CDC ACIP Meeting: COVID, Pneumococcal, Influenza, and RSV Vaccine Recommendations
October 24th 2024Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
Read More
Targeted Prophylaxis Reduces Hospital-Onset C difficile Infections in High-Risk Patients
October 22nd 2024The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
Read More
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing Immunity
October 22nd 2024John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Read More
Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges
October 21st 2024Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
Read More
Long COVID’s Impact on the Brain, Specifically Cognitive Function
In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.
Read More
First-Hand Insights into Treating Hepatitis C in Pregnancy
October 17th 2024Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Read More
Enhancing Outcomes in Outpatient Parenteral Antimicrobial Therapy
October 17th 2024Nabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.
Read More
Kalihinol Analog Targets Apicoplast Function In Malaria Treatment
October 17th 2024Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
Read More
Gilead's Phase 1a Trial Results Indicate GS-1720 as a Potential Long-Acting HIV Treatment
October 16th 2024GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.
Read More
Further Data Finds Lenacapavir to Be Safe and Tolerable for PrEP Use
Published: October 15th 2024 | Updated: October 15th 2024The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.
Read More
Unmasking Long COVID Through Understanding Prevalence and Diagnosis
In our latest roundtable series, the discussion addressed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.
Read More
The Underuse of COVID-19 Antiviral Treatments in Older Adults
October 11th 2024Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.
Read More